These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32523658)

  • 21. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
    Kuter DJ; Tarantino MD; Lawrence T
    Blood Rev; 2021 Sep; 49():100811. PubMed ID: 33781612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.
    Osman ME
    Sudan J Paediatr; 2012; 12(2):60-4. PubMed ID: 27493347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
    Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
    Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
    Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
    Song AB; Al-Samkari H
    Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia.
    Garzon AM; Mitchell WB
    Front Pediatr; 2015; 3():70. PubMed ID: 26322297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.
    Tumaini Massaro J; Chen Y; Ke Z
    Platelets; 2019; 30(7):828-835. PubMed ID: 30810479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
    J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Romiplostim as a treatment for immune thrombocytopenia: a review.
    Chalmers S; Tarantino MD
    J Blood Med; 2015; 6():37-44. PubMed ID: 25632241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.
    Grainger JD; Thind S
    Pediatr Hematol Oncol; 2017 Mar; 34(2):73-89. PubMed ID: 28537785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
    Barlassina A; González-López TJ; Cooper N; Zaja F
    Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists.
    Rottenstreich A; Bussel JB
    Br J Haematol; 2023 Dec; 203(5):872-885. PubMed ID: 37830251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
    Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
    Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.